Spyre Therapeutics, Inc.

Welcome to your essential guide to Spyre Therapeutics' annual performance for the fiscal year ended December 31, 2024. We've distilled the key information from their SEC 10-K filing, cutting through the technical language to provide you with a clear understanding of this clinical-stage biotechnology company's financial health, operational highlights, and future prospects. This summary focuses on major developments, financial figures, and potential risks, helping you grasp their mission to develop new therapies.

1. Business Overview

Spyre Therapeutics is a clinical-stage biotechnology company primarily focused on developing novel treatments for inflammatory bowel disease (IBD). It leverages its experimental drug candidates, including SPY001, SPY002, and SPY003, in this effort. Fiscal year 2024 was an active period for the company, marked by significant fundraising success and strategic pipeline management. Spyre secured substantial capital to advance its research and development efforts and streamlined its focus by divesting a non-core asset.

2. Financial Performance

As a development-stage company, Spyre Therapeutics does not yet generate significant product revenue. For fiscal year 2024, the company reported a net loss of approximately $117.2 million. This figure reflects the increase in its accumulated deficit, which grew from $159.3 million at the end of 2023 to $276.5 million by the end of 2024, showing a significant rise in losses from the previous year. Such losses are typical for biotech companies heavily investing in research before bringing products to market.

3. Management Discussion and Analysis (MD&A) Highlights

For the fiscal year ended December 31, 2024, Spyre Therapeutics' management focused on advancing its drug pipeline, raising capital strategically, and optimizing its asset portfolio.

Results of Operations and Strategic Developments: The company continued to incur significant net losses, typical for a clinical-stage company heavily investing in research and development. A key strategic decision was management's sale of the global rights to Pegzilarginase in July 2023 for $100 million. This divestiture enabled the company to sharpen its focus and direct resources mainly to its core inflammatory bowel disease (IBD) pipeline, including SPY001, SPY002, and SPY003, aiming for more efficient development. Management also made payments for license agreements related to these key drug candidates in 2024, indicating continued investment and commitment.

Liquidity and Capital Resources: Management successfully completed multiple financing rounds, significantly boosting the company's cash position. These included:

• $200 million in June 2023 through a private stock sale.
• $100 million in December 2023 through another private stock sale.
• $50 million in March 2024 through a private stock sale.
• An additional $15 million through "at-the-market" stock sales during 2024.
• A significant $100 million from a larger stock offering in November 2024. These fundraising efforts were critical for managing the substantial R&D and G&A expenses inherent in a clinical-stage biotech company.

Capital Structure Simplification: In 2024, management simplified its capital structure by converting all Series A and Series B preferred stocks into regular common stock. This move streamlined the company's ownership structure, potentially making it more attractive to common shareholders and simplifying future financial reporting.

4. Financial Health

Spyre Therapeutics ended fiscal year 2024 with a strong cash and investments position, reporting approximately $95 million in holdings in secure investments like money market funds, U.S. Treasury securities, and corporate bonds. This figure is projected to reach an estimated $190 million by the end of 2025, assuming it successfully completes planned future fundraising.

The company currently reports no significant debt, a positive sign of financial stability. Its consistent success in raising capital through stock offerings demonstrates strong liquidity and access to funds for its ongoing research and development pipeline. However, given its spending rate, continued access to capital is vital for long-term viability.

5. Future Outlook

Spyre Therapeutics has outlined clear plans for continued funding and pipeline advancement into 2025:

• Planned Fundraising: It anticipates raising an additional $15 million through an "at-the-market" offering and $100 million from an underwritten offering in 2025 to fund operations and development.
• Pipeline Development: The company's future depends on the progress of SPY001, SPY002, and SPY003. Continued investment in their development is central to its strategy.
• Anticipated Milestone Payments: Spyre expects to receive future revenue in 2025 from development milestones, including $10 million from the Paragon Agreement and $10 million from the Parapyre Option Obligation. These payments depend on achieving specific progress points in its development programs, potentially providing funding without issuing new shares.
• Board Expansion: The company expects to appoint new board members by the end of 2025 to further strengthen its governance and strategic oversight.